INMB - INmune Bio Inc. (INMB) Q4 2023 Earnings Call Transcript
2024-03-28 20:18:07 ET
INmune Bio, Inc. (INMB)
Q4 2023 Earnings Conference Call
March 28, 2024, 04:30 PM ET
Company Participants
RJ Tesi - Chief Executive Officer
David Moss - Chief Financial Officer
Mark Lowdell - Chief Scientific Officer
Conference Call Participants
Joel Beatty - Baird
Daniel Carlson - Tailwinds Research
Presentation
Operator
Ladies and gentlemen, greetings and welcome to the INmune Bio Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder this conference is being recorded. A transcript will follow within 24 hours of this conference call.
At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David, the floor is yours.
David Moss
Thank you, Ryan, and good afternoon everybody. We thank you for joining us for the call for INmune Bio's yearend 2023 financial results. With me on the call is Dr. RJ Tesi, CEO and Co-Founder of INmune Bio and Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder of INmune Bio, who will provide an update on INKmune, our memory-like natural killer cell oncology platform.
Before we begin, I remind everyone that except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligations to update these forward-looking statements to reflect future information events or circumstances....
INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript